Hi folks!  I haven’t done my regulatory news blog in a few months but I’m hoping to make it a regular thing again.  Here are the top regulatory news stories this week: On Tuesday the FDA had approved Abbvie’s Skyrizi (risankizumab-rzaa) for severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.[…]